Korean pharmaceutical researchers are advancing innovative approaches to overcome treatment resistance in ovarian cancer and improve delivery systems for obesity medications, according to presentations at recent academic conferences. These efforts reflect a broader push in South Korea’s pharmaceutical sector to integrate artificial intelligence and interdisciplinary research into drug development, addressing critical gaps in oncology and metabolic disease therapies.
The Korean Pharmaceutical Society’s spring academic conference, held in April 2026, featured research on novel strategies to combat platinum resistance in ovarian carcinoma, a major challenge in gynecologic oncology. Scientists from Seoul National University College of Pharmacy presented data showing that combining PARP inhibitors with epigenetic modulators could re-sensitize resistant tumor cells to chemotherapy in preclinical models. This approach targets the DNA repair pathways that ovarian cancer cells often exploit to evade treatment, offering a potential avenue for patients who relapse after initial response to platinum-based drugs.
In parallel, researchers at Korea University’s Department of Pharmacy demonstrated progress in developing oral delivery systems for glucagon-like peptide-1 (GLP-1) receptor agonists, the class of drugs behind popular obesity medications like semaglutide. Current GLP-1 therapies require subcutaneous injection, which limits patient adherence. The Korean team reported success in using nanoparticle-based encapsulation to protect the peptide from gastrointestinal degradation, enabling meaningful absorption in intestinal tracts during laboratory testing. If translated to human employ, such technology could significantly expand access to obesity treatment by eliminating the need for injections.
These projects were highlighted alongside broader discussions at the conference about the role of AI in accelerating drug discovery. Presentations from the Korea Institute of Science and Technology (KIST) described machine learning models trained on genomic and proteomic data to predict compound efficacy against specific cancer subtypes. One model identified three existing compounds with potential repurposing value for ovarian cancer, reducing the typical timeline for preclinical validation by an estimated 40%. Researchers emphasized that while AI accelerates hypothesis generation, all candidates still require rigorous laboratory and clinical validation before advancing to human trials.
The conference also addressed systemic challenges in translating academic research into commercial applications. Panel discussions involving representatives from the Ministry of Food and Drug Safety (MFDS) and the Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KPBMA) noted that South Korea filed approximately 1,200 pharmaceutical patents in 2025, with oncology and metabolic disease therapies accounting for nearly 35% of submissions. However, only about 18% of academic-industry collaborative projects progress beyond Phase I clinical trials, often due to funding gaps and regulatory complexity in early-stage development.
To bridge this gap, the MFDS announced a pilot program in March 2026 to streamline preclinical-to-clinical transition for high-potential academic discoveries. The initiative provides regulatory consultation and access to shared manufacturing facilities for projects targeting unmet medical needs, including rare cancers and metabolic disorders. Five projects were selected for the first cohort, two of which focus on ovarian cancer resistance mechanisms and oral peptide delivery systems.
Experts cautioned that while early results are promising, significant hurdles remain before these technologies reach patients. Ovarian cancer heterogeneity means that resistance mechanisms vary widely between individuals, requiring personalized approaches that current delivery systems may not accommodate. Similarly, oral peptide drugs face challenges in achieving consistent bioavailability across diverse populations, with factors like gastric pH and intestinal motility affecting absorption rates.
Looking ahead, researchers called for increased investment in longitudinal studies to assess long-term safety and efficacy of novel drug combinations and delivery platforms. The Korean Pharmaceutical Society plans to host a follow-up symposium in October 2026 to review progress on these initiatives, with updated data expected from ongoing preclinical studies and early-phase clinical trials.
For official updates on pharmaceutical research regulations and funding opportunities in South Korea, visit the Ministry of Food and Drug Safety’s English-language portal or the Korea Pharmaceutical and Bio-Pharma Manufacturers Association’s industry resources page.